This Week’s Top Stories in Biotech
Most Popular - Jason Napodano laid out the DRRX investment thesis. Will Pfizer re-file the Remoxy NDA? And what about Posidur? They’re both real value drivers for DRRX, … Continue Reading
Read nowSearch Results for remoxy
PropThink’s End-of-Week Recap
Most Popular - We spent the week in San Francisco for the JP Morgan and Biotech Showcase conferences, which proved invaluable for idea generation, networking, and the solidifying of some … Continue Reading
Read nowPropThink’s Weekly Healthcare Wrap-Up
Most Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read nowPTIE Down on Disappointing Pfizer Commentary and Pushback; Stock Could Trade Lower
Short Ideas - Shares of Pain Therapeutics (NASDAQ:PTIE) are off 25% as partner Pfizer (NYSE:PFE) noted Thursday on its earnings call that Remoxy, PTIE’s lead product, is a … Continue Reading
Read nowA Glance At This Week's Top Healthcare Stories
Recap - Shares of HEB furtively peaked on Monday following an announcement that Ampligen’s advisory committee meeting date had been set, but shares were unsuccessful in maintaining … Continue Reading
Read nowA Look Back At This Week's Top Stories
Recap - Questcor Pharmaceuticals imploded. We said shares would rebound after tuning into the company’s conference call and coming out thinking Questcor’s lead product, H.P. Acthar Gel, … Continue Reading
Read now